These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 7192203

  • 1. Combined chronochemotherapy of L1210 leukemic mice using 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine, methylprednisolone and cis-diamminedichloroplatinum.
    Scheving LE, Burns ER, Halberg F, Pauly JE.
    Chronobiologia; 1980; 7(1):33-40. PubMed ID: 7192203
    [Abstract] [Full Text] [Related]

  • 2. Survival and cure of leukemic mice after circadian optimization of treatment with cyclophosphamide and 1-beta-D-arabinofuranosylcytosine.
    Scheving LE, Burns ER, Pauly JE, Halberg F, Haus E.
    Cancer Res; 1977 Oct; 37(10):3648-55. PubMed ID: 908013
    [Abstract] [Full Text] [Related]

  • 3. Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.
    Burns ER, Scheving LE.
    Chronobiologia; 1980 Oct; 7(1):41-51. PubMed ID: 7438892
    [No Abstract] [Full Text] [Related]

  • 4. Chronochemotherapy of L1210 leukemic mice with cytosine arabinoside or cyclophosphamide.
    Rose WC, Trader MW, Laster WR, Schabel FM.
    Cancer Treat Rep; 1978 Sep; 62(9):1337-49. PubMed ID: 688277
    [No Abstract] [Full Text] [Related]

  • 5. Basis of observed resistance of L1210 leukemia in mice: methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, and 1-beta-D-arabinofuranosylcytosine administered in different combinations.
    Kim K, Blechman WJ, Riddle VG, Pardee AB.
    Cancer Res; 1981 Nov; 41(11 Pt 1):4529-34. PubMed ID: 7198006
    [Abstract] [Full Text] [Related]

  • 6. Chronochemotherapy: L 1210 leukemia and beyond.
    Halberg F, Nelson W, Cornélissen G, Haus E, Scheving LE, Good RA.
    Chronobiologia; 1979 Nov; 6(3):203-11. PubMed ID: 520097
    [Abstract] [Full Text] [Related]

  • 7. Sequential administration of two oncostatic drugs: study of modalities for pharmacodynamic potentiation.
    Pouillart R, Huong TH, Brugerie E, Lheritier J.
    Biomedicine; 1974 Dec 10; 21(12):471-9. PubMed ID: 4462870
    [No Abstract] [Full Text] [Related]

  • 8. Single versus combination chemotherapy of L1210 leukemia.
    Koza I, Balázová E, Ujházy V.
    Neoplasma; 1980 Dec 10; 27(6):691-6. PubMed ID: 7254424
    [Abstract] [Full Text] [Related]

  • 9. Effects of 2'-deoxycoformycin, 9-beta-D-arabinofuranosyladenine 5'-phosphate, and 1-beta-D-arabinofuranosylcytosine triple combination therapy on intracerebral leukemia 1210.
    Caron N, Lee SH, Kimball AP.
    Cancer Res; 1977 Sep 10; 37(9):3274-9. PubMed ID: 884674
    [Abstract] [Full Text] [Related]

  • 10. Uptake, initial effects, and chemotherapeutic efficacy of harringtonine in murine leukemic cells sensitive and resistant to vincristine and other chemotherapeutic agents.
    Chou TC, Schmid FA, Feinberg A, Philips FS, Han J.
    Cancer Res; 1983 Jul 10; 43(7):3074-9. PubMed ID: 6189591
    [Abstract] [Full Text] [Related]

  • 11. Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia.
    Avery TL, Roberts D.
    Cancer Res; 1977 Mar 10; 37(3):678-83. PubMed ID: 837368
    [Abstract] [Full Text] [Related]

  • 12. Combination chemotherapy in sequence for the treatment of L1210 leukemia.
    Roberts D, Hilliard SL.
    Cancer Res; 1978 Aug 10; 38(8):2317-20. PubMed ID: 667827
    [No Abstract] [Full Text] [Related]

  • 13. Electronic volume analysis of L1210 chemotherapy.
    Zucker RM, Helfman D.
    Cancer Res; 1976 Dec 10; 36(12):4434-8. PubMed ID: 1000492
    [Abstract] [Full Text] [Related]

  • 14. [Chemotherapy of L1210 leukemia: comparison of 7 drugs given either continuously for 20 days, or in a single massive dose, early or late].
    Mathé G, Schwarzenberg L, Hayat M, Schneider M.
    Rev Fr Etud Clin Biol; 1968 Dec 10; 13(10):951-60. PubMed ID: 5306738
    [No Abstract] [Full Text] [Related]

  • 15. Combined effect of cytostatic drugs and E-N-L-trimethyl lysine in healthy and transplantable tumor bearing mice.
    Szende B, Lapis K, Simon K.
    Neoplasma; 1982 Dec 10; 29(4):427-39. PubMed ID: 6813749
    [Abstract] [Full Text] [Related]

  • 16. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.
    Ramonas LM, Erickson LC, Ringsdorf H, Zaharko DS.
    Cancer Res; 1980 Oct 10; 40(10):3704-8. PubMed ID: 7438053
    [Abstract] [Full Text] [Related]

  • 17. Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice.
    Neil GL, Moxley TE, Manak RC.
    Cancer Res; 1970 Aug 10; 30(8):2166-72. PubMed ID: 4990003
    [No Abstract] [Full Text] [Related]

  • 18. [L 1210 leukemia, an experimental model for the potentiation of drugs used for acute leukemias].
    Pouillart P, Huong TH, Lhéritier J.
    Bull Cancer; 1974 Aug 10; 61(4):509-26. PubMed ID: 4458834
    [No Abstract] [Full Text] [Related]

  • 19. Optimum time sequence for the administration of vincristine and cyclophosphamide in vivo.
    Razek A, Vietti T, Valeriote F.
    Cancer Res; 1974 Aug 10; 34(8):1857-61. PubMed ID: 4842737
    [No Abstract] [Full Text] [Related]

  • 20. Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151).
    Woodman RJ.
    Cancer Chemother Rep 2; 1974 Mar 10; 4(1):45-52. PubMed ID: 4826499
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.